ReviewCurrent opinion in allergy and clinical immunology2014
Refining gold from existing data.
Review in Current opinion in allergy and clinical immunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Interoperability of health data using FHIR Mapping Language: transforming HL7 CDA to FHIR with reusable visual components.Frontiers in digital health · 2024Article
- A reference architecture for personal health data spaces using decentralized content-addressable storage networks.Frontiers in medicine · 2024Article
- Article
- Traits and types of health data repositories.Health information science and systems · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
purpose of reviewThe purpose is to review the arguments for increasing use of existing data in health research. RECENT
findingsThe reuse of data in observational, exploratory and outcome studies, as well as in confirming other findings, is being justified on epistemological grounds as the major path to new knowledge and to the generalizing of findings to 'real world' populations. It is also justified on the grounds of cost, power, and efficiency, even though data reuse comes with real informatics, scientific culture, societal, and regulatory issues. SUMMARY: Data reuse is becoming more compelling. When contemplating new research for any purpose other than RCTs for efficacy, it is prudent to consider whether partnership with existing data holders should be part of the optimal research plan.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.